New cardiovascular, kidney and cognitive outcome data is reframing GLP-1 receptor agonists as potential healthspan drugs, not just appetite suppressants.
GLP-1 receptor agonists are no longer just diabetes or obesity drugs. The 2025–2026 outcome trials show meaningful reductions in cardiovascular events, kidney decline and early signals on neurodegeneration.
The anti-aging supplement market is loud, expensive and full of half-truths. We graded the most-hyped compounds against actual human trial data so you can build a stack that does something.
Intermittent low-dose rapamycin keeps producing the most consistent lifespan signal of any drug tested in mammals. Here is what the 2026 data adds, and how serious longevity protocols are evolving.
Both NMN and NR reliably raise NAD+, but the functional outcomes — energy, muscle, vascular health — depend heavily on dose, form and what you stack them with.
Two minutes, no blood test, no sign-up — find out how you are actually ageing, and what to do about it.
One email a week: what changed in the evidence, what it means for the markers you track, and the occasional thing worth stopping. No spam, unsubscribe anytime.